<DOC>
	<DOCNO>NCT01204073</DOCNO>
	<brief_summary>This first study TAK-441 administer human . The patient population consist adult age 18 old advance nonhematologic malignancy standard treatment longer effective offer curative life-prolonging potential . Following completion dose escalation study , patient enrol part 2 expansion cohort .</brief_summary>
	<brief_title>A Study TAK-441 Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Male female 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Diagnosis nonhematologic malignancy standard treatment longer effective offer curative lifeprolonging potential Meet clinical , radiographic laboratory inclusion criterion specify protocol Voluntary write consent Patients meet follow exclusion criterion enrol study : Lifethreatening illness unrelated cancer Receiving treatment ( radiotherapy , antineoplastic investigational agent ) within protocol specify window first dose TAK441 Patients brain metastasis meet criterion specify study protocol Known history human immunodeficiency virus ( HIV ) infection , hepatitis B hepatitis C Major surgery within 14 day first dose TAK441 Infection require systemic therapy , serious infection within 14 day first dose TAK441 Do meet clinical , laboratory radiographic criterion specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>